Table 4.
Name of Vaccine (Ref.) |
Phase | Introduction | Methodology | Sex Disaggregation | Discussion | Generalizability | No. of Doses * |
---|---|---|---|---|---|---|---|
CoronaVac [59] | III | No | No | No | No | No | 367 million |
AstraZeneca ** [60] | II/III | No | No | No | No | No | 3009 million |
Sputnik V [28] | III | No | No | Yes (immunogenicity) | No | No | 765 million |
Moderna [29] | III | No | No | Yes (efficacy) | No | No | 816 million |
Pfizer-BioNTech [24] | III | No | No | Yes (efficacy) | No | Yes | 1220 million |
Janssen [16] | III | No | No | Yes (efficacy) | No | No | 368 million |
** Number of doses ordered as of 28 May 2021 based on data from Statistica (59); * Phase III AstraZeneca paper yet to be published as of 22 April 2021 when our search was conducted.